EUVIMEDEUVIMED entdecken
Crossref

Curation of OCA2 Variants of Uncertain Significance From Chinese Oculocutaneous Albinism Patients Based on Multiplex Assays

Qingsong Yang iD, Yizhen Wang iD, Zengge Wang iD, Shushu Lv iD, Zhenhua Hao iD, Aihua Wei iD, Wei Li iD

Pigment Cell & Melanoma Research · 2025

DOI: 10.1111/pcmr.13212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, 2025. Verfasst von Qingsong Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, Genetics and Birth Defects Control Center, National Cente…. Hauptthemen laut MEDLINE: Albinism, Oculocutaneous, Membrane Transport Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oculocutaneous albinism type 2 (OCA‐2, OMIM: 203200) is associated with variants in the OCA2 gene. In this study, we aimed to re‐classify variants of uncertain significance (VUS) in OCA2 by evaluating subcellular localization and channel activity through multiplex assays of variant effect (MAVEs). Following the ClinGen guidelines for PS3 evidence, we selected 13 OCA2 variants from ClinVar (6 benign/likely benign [B/LB] and 7 pathogenic/likely pathogenic [P/LP]) for OddsPath analysis. The P/LP variants exhibited abnormal functions, while the B/LB variants demonstrated normal functions, supporting the application of “PS3_moderate” evidence for VUS re‐classification. In our functional evaluation of 30 VUS identified in 38 individuals with suspected OCA‐2 by trio whole‐exome sequencing, we observed 6 VUS with abnormal localization and 11 with abnormal channel activity. Based on PS3_moderate evidence, 8 VUS were re‐classified as LP, while 22 remained VUS. Consequently, 7 out of 38 previously undiagnosed patients received a molecular diagnosis of OCA‐2. These MAVEs offer a robust approach for curating OCA2 VUS, enhancing diagnostic accuracy, and informing genetic counseling. Additionally, this variant cohort is a valuable resource for public databases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Albinism, OculocutaneousMembrane Transport ProteinsFemaleHumansMaleChinaEast Asian PeopleExome SequencingGenetic VariationMutation

Stichwörter der Autor:innen

functional assayoculocutaneous albinism type 2patch‐clampingpathogenicityvariant interpretation

Substanzen

Membrane Transport ProteinsOCA2 protein, human

Autor:innen und Institutionen

  • Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, Genetics and Birth Defects Control Center, National Center for Children's Health, MOE Key Laboratory of Major Diseases in Child…
  • Department of Dermatology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Qingsong Yang, Yizhen Wang, Zengge Wang, Shushu Lv, Zhenhua Hao, Aihua Wei, Wei Li

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • National Natural Science Foundation of China

Zitieren

APA

Yang, Q., Wang, Y., Wang, Z., Lv, S., Hao, Z., Wei, A., & Li, W. (2025). Curation of OCA2 Variants of Uncertain Significance From Chinese Oculocutaneous Albinism Patients Based on Multiplex Assays. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.13212

Vancouver

Yang Q, Wang Y, Wang Z, Lv S, Hao Z, Wei A, et al. Curation of OCA2 Variants of Uncertain Significance From Chinese Oculocutaneous Albinism Patients Based on Multiplex Assays. Pigment Cell & Melanoma Research. 2025. doi:10.1111/pcmr.13212

BibTeX
@article{Yang2025,
  author = {Yang, Qingsong and Wang, Yizhen and Wang, Zengge and Lv, Shushu and Hao, Zhenhua and Wei, Aihua and Li, Wei},
  title = {Curation of OCA2 Variants of Uncertain Significance From Chinese Oculocutaneous Albinism Patients Based on Multiplex Assays},
  journal = {Pigment Cell & Melanoma Research},
  year = {2025},
  doi = {10.1111/pcmr.13212}
}
Kostenlos starten →